Drug delivery of hydroxyurea to breast cancer using liposomes

被引：22

作者：

Alavi S.E. ^{[1
]}

Esfahani M.K.M. ^{[1
]}

Alavi F. ^{[1
]}

Movahedi F. ^{[1
]}

Akbarzadeh A. ^{[2
]}

机构：

[1] Department of Chemical Engineering, Lamerd Branch, Islamic Azad University, Lamerd

[2] Department of Pilot Biotechnology, Pasteur Institute of Iran, Tehran

来源：

Indian Journal of Clinical Biochemistry | 2013年 / 28卷 / 3期

关键词：

Breast cancer; Hydroxyurea; Liposomal; Nano drug delivery;

D O I：

10.1007/s12291-012-0291-y

中图分类号：

学科分类号：

摘要：

It is clear that cancer is one of the most mortal diseases in the world and the most prevalent among women is breast cancer. As hydroxyurea (HU) - a drug which is used in chemotherapy - has many adverse effects in long-term despite of its therapeutic properties, we made use of nano drug delivery technology in order to reduce adverse effects and increase therapeutic index. Thus, liposomation is a novel way in drug delivery systems. In this study a mixture of phosphatidylcholine and cholesterol was mixed and HU was added to the resultant mixture. The mean diameter of the nanoliposomal HU measured with the Zeta Sizer device (equal to 402.5 nm) and its encapsulation efficiency was 70.8 %. Besides, using dialysis, the pattern of drug release from nanoliposomes has been studied and the results showed that the drug release of nanoliposomal drug within 28 h was equal to 25.85 %. This study showed that the cytotoxicity effect of nanoliposomal drug is more than that of the standard drug. © 2012 Association of Clinical Biochemists of India.

引用

页码：299 / 302

页数：3

共 17 条

[1]

Guo J., Bourre L., Soden D.M., O'Sullivan G.C., O'Driscoll C., Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?, Biotechnol Adv, 29, pp. 402-417, (2011)

[2]

Vo A.T., Millis R.M., Epigenetics and breast cancers, Obstet Gynecol Int, 2012, (2012)

[3]

Pathy N.B., Yip C.H., Taib N.A., Hartman M., Saxena N., Iau P., Et al., Singapore-Malaysia breast cancer working group. Breast cancer in a multi-ethnic asian setting: Results from the Singapore-Malaysia hospital-based breast cancer registry, Breast, 20, pp. 75-80, (2011)

[4]

Sadjadi A., Nouraie M., Mohagheghi M.A., Mousavi-Jarrahi A., Malekezadeh R., Parkin D.M., Cancer occurrence in Iran in 2002, an international perspective, Asian Pac J Cancer Prev, 6, pp. 359-363, (2005)

[5]

Harirchi I., Ebrahimi M., Zamani N., Jarvandi S., Montazeri A., Breast cancer in Iran: A review of 903 case records, Public Health, 114, pp. 143-145, (2000)

[6]

Rezaianzadeh A., Peacock J., Reidpath D., Talei A., Hosseini S.V., Mehrabani D., Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran, BMC Cancer, 9, (2009)

[7]

Lanzkron S., Strouse J.J., Wilson R., Beach M.C., Haywood C., Park H., Et al., Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease, Ann Intern Med, 148, pp. 939-955, (2008)

[8]

Meo A., Cassinerio E., Castelli R., Bignamini D., Perego L., Cappellini M.D., Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: Case reports and literature review, Int J Lab Hematol, 30, pp. 425-431, (2008)

[9]

Zaccaria E., Cozzani E., Parodi A., Secondary cutaneous effects of hydroxyurea: Possible pathogenetic mechanisms, J Dermatolog Treat, 17, pp. 176-178, (2006)

[10]

Sirieix M.E., Debure C., Baudot N., Dubertret L., Roux M.E., Morel P., Et al., Leg ulcers and hydroxyurea: Forty-one cases, Arch Dermatol, 135, pp. 818-820, (1999)

← 1 2 →